Johnson & Johnson
JNJ (NYSE)
Johnson & Johnson stands out as a top-rated healthcare company with products that maintain durable demand across economic cycles, making it an attractive option for UK investors through its US listing. With a solid dividend yield of 2.28%, it has delivered impressive returns of 50.20% over the past year and 36.35% over five years, reflecting strong financial health and reliable income. Analysts have a median 12-month price target of $252.50, with some upgrades indicating positive sentiment about its growth potential.
Pros:
- Strong historical performance
- Diverse product portfolio
Cons:
- Recent earnings growth slower than industry
- Market competition
Johnson & Johnson (JNJ) may be a suitable investment for those seeking a combination of capital appreciation and reliable income through dividends, particularly for investors looking for stability in the healthcare sector. Its strong historical performance and positive analyst outlook suggest it could be a valuable addition to a diversified portfolio, especially for those looking to invest in resilient companies with consistent demand.